Genaissance Pharmaceuticals and Ferring Pharmaceuticals Sign Pharmacogenomics Agreement
Thursday December 11, 7:31 am ET
NEW HAVEN, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has entered into an agreement with Ferring Pharmaceuticals A/S under which Genaissance will provide certain pharmacogenomic services and technology to Ferring.
Under the agreement, Genaissance will provide to Ferring pharmacogenomic expertise including GLP-compliant DNA banking services through its Morrisville, NC, operations. Genaissance will also collaborate with Ferring to identify clinical projects for the application of Genaissance's HAP(TM) Technology.
"We are pleased to be working with Ferring Pharmaceuticals. Ferring holds a global leadership position in key therapeutic areas, making us extremely pleased to have been chosen by them to provide pharmacogenomics technology and services," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "This agreement also expands our own global positioning, progressing our entry into serving the European pharmaceutical industry."
About Ferring Pharmaceuticals
Ferring Pharmaceuticals, founded in 1950, is a research-driven specialty biopharmaceutical group active in global markets. The group identifies, develops and markets innovative products in the fields of urology, gynecology, gastroenterology and endocrinology. Ferring operates in more than 40 countries. Visit the company's website at www.ferring.com... |
